Summary
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve
BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding; Q2 2026 revenue reached $218.3M, with strong gross margins and positive cash flow independent of licensing receipts. The navenibart acquisition positions BCRX to capture injectable-preferring HAE patients, leveraging existing commercial infrastructure for operating leverage and customer retention.
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model
Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential.
Haemonetics Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 201 | $15,099.96 | $20,395.47 | $5,295.51 | 35.07% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 4,789 | $359,180 | $484,503.13 | $125,323.13 | 34.89% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 2,110 | $158,000 | $213,468.7 | $55,468.7 | 35.11% |
| NA Nizar Araji National Bank Of Canada /FI/ | 4,500 | $238,680 | $395,280 | $156,600 | 65.61% |
 John W. Rogers Jr Ariel Investment LLC | 2.06M | $154.57M | $187.14M | $32.56M | 21.07% |
Haemonetics Corporation (HAE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Haemonetics Corporation ever had a stock split?
Haemonetics Corporation Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Christopher A. Simon CEO | NYSE Exchange | 405024100 CUSIP |
| US Country | 3,009 Employees | - Last Dividend | 3 Dec 2012 Last Split | 9 May 1991 IPO Date |
Overview
Haemonetics Corporation is a leading healthcare provider that specializes in developing a comprehensive suite of medical products and solutions. With a global presence, the company is dedicated to enhancing the efficiency and safety of blood and plasma collection, processing, and management. Founded in 1971 and headquartered in Boston, Massachusetts, Haemonetics Corporation has been at the forefront of innovation, offering advanced technologies to support hospitals, blood banks, and plasma collection centers in improving patient care and outcomes.
Products and Services
- Automated Plasma Collection Systems and Software Solutions:
Includes NexSys PCS and PCS2 plasmapheresis equipment, related disposables, and intravenous solutions. Offers integrated IT platforms like NexLynk DMS donor management system and Donor360, designed for plasma customers to streamline donor management, operations, and supply chain management.
- Automated Blood Component and Manual Whole Blood Collection Systems:
Features the MCS brand apheresis equipment, which enables the collection of specific blood components from donors. Also provides disposable collection and component storage sets, SafeTrace Tx blood bank information system, and BloodTrack management software, facilitating efficient blood management and transfusion processes.
- Hospital Products:
Offers TEG, ClotPro, and HAS hemostasis analyzer systems for a comprehensive assessment of a patient's hemostasis. TEG Manager software connects TEG analyzers across the hospital, allowing clinicians remote access to test results to inform treatment decisions. Cell Saver Elite +, an autologous blood recovery system, is suited for various surgeries, enhancing recovery and minimizing transfusion needs.
- VASCADE Products:
Including VASCADE and VASCADE MVP, this technology platform leverages the natural clotting mechanism with a catheter-based delivery system for vascular closure, designed to improve patient outcomes and reduce recovery time after procedures.
